Serum 25-Hydroxy Vitamin D Level Does Not Reflect The Severity of Wart: A Cross-Sectional Study

Yıl 2022, Cilt: 17 Sayı: 2, 15 - 19, 15.07.2022

Gökşen Ertuğrul Habibullah Aktaş

https://doi.org/10.17517/ksutfd.987056

Öz

Objective: Verruca vulgaris is a benign epithelial proliferative disease caused by human papilloma viruses. Topical and intralesional vitamin D applications are effective methods in the treatment of warts. However, the relationship between the disease and serum vitamin D levels is unclear. The correlation between the severity of the disease and serum 25-hydroxy vitamin D (25-OH vit D) levels have not been previously investigated. This study aimed to determine the relationship between serum 25-OH vit D levels and disease severity in patients with verruca vulgaris.
Material and Methods: Serum 25-OH vit D levels were evaluated in 40 patients with verruca vulgaris and 43 sex and age-matched healthy volunteers. Serum 25-OH vit D levels were compared by grouping the patients according to the severity and duration of verruca vulgaris disease Results: There was no significant difference in serum 25-OH vit D levels between verruca vulgaris patients and the control group (p=0.760). There was no significant difference between serum 25-OH vit D level, disease severity and disease duration in the verruca vulgaris group (p =0.102, p=0.257, respectively).
Conclusion: Serum 25-OH vit D level was not associated with verruca vulgaris. Serum 25-OH vit D levels are not related to disease severity and duration. Our data do not support vitamin D supplementation for the prevention or treatment of verruca vulgaris.

Anahtar Kelimeler

Disease severity, Serum 25-hydroxy vitamin D, Verruca vulgaris

Destekleyen Kurum

Yok.

Proje Numarası

-

Teşekkür

-

Serum 25-Hidroksi Vitamin D Düzeyi Siğil Şiddetini Yansıtmaz: Kesitsel Bir Çalışma

Öz

Amaç: Verruka vulgaris, human papilloma virüslerinin neden olduğu benign epiteliyal proliferatif bir hastalıktır. Siğil tedavisinde topikal ve intralezyonel D
vitamini uygulamaları etkili yöntemlerdir. Bununla birlikte, hastalık ile serum D vitamini düzeyleri arasındaki ilişki belirsizdir. Hastalığın şiddeti ile serum 25-hidroksi D vitamini (25-OH vit D) düzeyleri arasındaki ilişki daha önce araştırılmamıştır. Bu çalışmada verruka vulgarisli hastalarda serum 25-OH vit D düzeyleri ile hastalık şiddeti arasındaki ilişkinin belirlenmesi amaçlanmıştır.
Gereç ve Yöntemler: Verruka vulgarisli 40 hasta ile cinsiyet ve yaş açısından eşleştirilmiş 43 sağlıklı gönüllünün serum 25-OH vit D düzeyleri ölçüldü. Hastalar verruka vulgaris hastalık şiddeti ve süresine göre gruplandırılarak serum 25-OH vit D düzeyleri kaşılaştırıldı.
Bulgular: Verruka vulgaris hastaları ile kontrol grubu arasında serum 25-OH vit D düzeylerinde anlamlı fark yoktu (p=0.760). Hastalar verruka vulgaris hastalık şiddeti ve süresine göre gruplandırıldığında hafif hastalığı olanlar ile şiddetli hastalığı olanlar arasında serum 25-OH vit D düzeyleri farklı değildi.
Sonuç: Serum 25-OH vit D düzeyi verruka vulgaris ile ilişkili değildir. Serum 25-OH vit D düzeyleri hastalık şiddeti ve süresi ile de ilişkili değildir. Verilerimiz verruka vulgarisin önlenmesi veya tedavisi için D vitamini takviyesini desteklememektedir.

Anahtar Kelimeler

Hastalık şiddeti, Serum 25-hidroksi D vitamini, Verruka vulgaris

Proje Numarası

-

Kaynakça

• Egawa K, Ono T. Topical vitamin D3 derivatives for recalcitrant warts in three immunocompromised patients. Br J Dermatol. 2004;150(2):374–376.
• Mitsuhashi Y, Kawaguchi M, Hozumi Y, Kondo S. Topical vitamin D3 is effective in treating senile warts possibly by inducing apoptosis. J Dermatol. 2005;32(6):420–423.
• Imagawa I, Suzuki H. Successful treatment of refractory warts with topical vitamin D3 derivative (maxacalcitol, 1 alpha, 25-dihydroxy-22-oxacalcitriol) in 17 patients. J Dermatol. 2007;34(4):264–266.
• Moscarelli L, Annunziata F, Mjeshtri A, Paudice N, Tsalouchos A, Zanazzi M et al. Successful treatment of refractory wart with a topical activated vitamin d in a renal transplant recipient. Case Rep Transplant. 2011;2011:368623.
• Osborne JE, Hutchinson PE. Vitamin D and systemic cancer: is this relevant to malignant melanoma? Br J Dermatol. 2002;147(2):197–213.
• Aktaş H, Ergin C, Demir B, Ekiz Ö. Intralesional vitamin D injection may be an effective treatment option for warts. J Cutan Med Surg. 2016;20(2):118–122.
• Raghukumar S, Ravikumar BC, Vinay KN, Suresh MR, Aggarwal A, Yashovardhana DP. Intralesional Vitamin D3 Injection in the Treatment of Recalcitrant Warts: A Novel Proposition. J Cutan Med Surg. 2017;21(4):320–324.
• Kavya M, Shashikumar BM, Harish MR, Shweta BP. Safety and efficacy of intralesional vitamin D3 in cutaneous warts: an open uncontrolled trial. J Cutan Aesthet Surg. 2017;10(2):90–94.
• Jakhar D, Kaur I, Misri R. Intralesional vitamin D3 in periungual warts. J Am Acad Dermatol. 2019;80(5):111–112.
• Öztekin C, Öztekin A, Taştan K, Özmen GG, Pektaş SD. The association between verruca vulgaris and vitamin D: is there a casual link? Acta Medica Mediterranea, 2018,34(4):1047–1050.
• Tamer F, Yuksel ME, Karabag Y. Pre-treatment vitamin B12, folate, ferritin, and vitamin D serum levels in patients with warts: a retrospective study. Croat Med J. 2020;61(1):28–32.
• Mostafa WZ, Hegazy RA. Vitamin D and the skin: Focus on a complex relationship: a review. J Adv Res. 2015;6(6):793–804.
• Yakoob MY, Salam RA, Khan FR, Bhutta ZA. Vitamin D supplementation for preventing infections in children under five years of age. Cochrane Database Syst Rev. 2016;11:CD008824.
• Kechichian E, Ezzedine K. Vitamin D and the skin: An update for dermatologists. Am J Clin Dermatol. 2018;19(2):223–235.
• Muehleisen B, Bikle DD, Aguilera C, Burton DW, Sen GL, Deftos LJ et al. PTH/PTHrP and vitamin D control antimicrobial peptide expression and susceptibility to bacterial skin infection. Sci Transl Med. 2012 May 23;4(135):135ra66.
• Bergler-Czop B, Brzezin ´ska-Wcisło L. Serum vitamin D level: the effect on the clinical course of psoriasis. Postepy Dermatol Alergol. 2016;33(6):445–449.
• Heine G, Hoefer N, Franke A, Nothling U, Schumann RR, Hamann L et al. Association of vitamin D receptor gene polymorphisms with severe atopic dermatitis in adults. Br J Dermatol. 2013;168(4):855–858.
• Upala S, Sanguankeo A. Low 25-hydroxyvitamin D levels are associated with vitiligo: a systematic review and meta-analysis. Photodermatol Photoimmunol Photomed. 2016;32(4):181– 190.
• Aksu Cerman A, Sarikaya Solak S, Kivanc Altunay I. Vitamin D deficiency in alopecia areata. Br J Dermatol. 2014;170(6):1299– 1304.
• Incel Uysal P, Alli N, Hayran Y, Candar T. Mycosis Fungoides and Vitamin D Status: Analyses of serum 25-Hydroxyvitamin D Levels and single nucleotide polymorphisms in the Vitamin D Receptor Gene. Acta Dermatovenerol Croat. 2018;26(1):8-14.
• Mok CC, Birmingham DJ, Ho LY, Hebert LA, Song H, Rovin BH. Vitamin D deficiency as marker for disease activity and damage in systemic lupus erythematosus: a comparison with anti-dsDNA and anti-C1q. Lupus. 2012;21(1):36–42.
• Giuggioli D, Colaci M, Cassone G, Fallahi P, Lumetti F, Spinella A et al. Serum 25-OH vitamin D levels in systemic sclerosis: analysis of 140 patients and review of the literature. Clin Rheumatol. 2017;36(3):583–590.
• Lim SK, Ha JM, Lee Y, Seo YJ, Kim CD, Lee JH et al. Comparisonof vitamin D levels in patients with and without acne: A case-control study combined with a randomized controlled trial. PloSOne. 2016;11(8):e0161162.
• Kemeriz F, Tuncer SÇ, Acar EM, Tuğrul B. Evaluation of 25-hydroxy vitamin D levels and disease severity in patients with acne vulgaris [published online ahead of print, 2020 Apr 8]. Dermatol Ther. 2020;33(3):e13393.
• Navarro-Triviño FJ, Arias-Santiago S, Gilaberte-Calzada Y. Vitamin D and the skin: A review for dermatologists. Actas Dermosifiliogr. 2019;110(4):262-272.
• Solak I, Cihan FG, Mercan S, Kethuda T, Eryılmaz MA. Evaluation of 25-hydroxyvitamin D levels in central Anatolia, Turkey. Biomed Res Int. 2018;2018:4076548.